Loading
Every dated change on the records linked to Borderline resectable pancreatic ductal adenocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
One-year overall survival 39 percent with immediate surgery against 78 percent with neoadjuvant gemcitabine plus capecitabine, 84 percent with FOLFIRINOX and 60 percent with chemoradiotherapy (p 0.
A milestone in how this cancer is treated.
18-month overall survival 66.
5-year OS 20.
A milestone in how this cancer is treated.